The entry of antiviral and antiretroviral drugs into the central nervous system

Journal of NeuroVirology

Volumn 3, Issue 6, 1997, Pages 387-400

  Groothuis, Dennis R ^a,b,c   Levy, Robert M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University Medical School ^*  (United States)

Author keywords

Antiretroviral; Antisense; Antiviral; Blood brain barrier; CSF; Nucleoside; Zidovudine

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CYTARABINE; DIDANOSINE; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

ANIMAL TISSUE; BLOOD BRAIN BARRIER; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; EXTRACELLULAR FLUID; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MATHEMATICAL ANALYSIS; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0031475151     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550289709031185     Document Type: Review

References (106)

1. Agrawal S (1991). Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. In Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. Wickstrom E (cd): Wiley-Liss: New York, pp. 142-158.
2. Agrawal S, Temsamani J et al (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599.
3. Anderson BD, Hoesterey BL et al (1990). Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats; intravenous infusion studies. J Pharmacol Exp Ther 253: 113-118.
4. Archer DP, Labrecque P et al (1987). Cerebral blood volume is increased in dogs during administration of nitrous oxide or isoflurance. Anesthesiology 67: 642-648.
5. Artru AA (1987). Reduction of cerebrospinal pressure by hypocapnia: changes in cerebral blood volume, cerebrospinal fluid volume, and brain tissue water and electrolytes. J Cereb Blood Flow Metab 7: 471-479.
6. Betz AL, Goldstein GW et al (1994). Blood-Brain-Cerebrospinal Fluid Barriers. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Siegel GJ (ed): Raven Press: New York, pp. 681-699.
7. Blasberg RG (1977). Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat Rep 61: 625-631.
8. Blasberg RG, Groothuis DR (1986). Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Sem Oncol 13: 70-83.
9. Blasberg RG, Patlak C et al (1975). Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195: 78-83.
10. Blasberg RG, Patlak CS et al (1977). Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 61: 633-641.
11. Blasberg RG, Patlak CS et al (1983a). Selection of experimental conditions for the accurate determination of blood-brain transfer constants from single-time experiments: a theoretical analysis. J Cereb Blood Flow Metab 3: 215-225.
12. Blasberg RG, Patlak CS et al (1983b). The transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 3: 8-32.
13. Boado RJ (1995). Antisense drug delivery through the blood-brain barrier. Advanced Drug Deliv Rev 15: 73-107.
14. Boado RJ, Kang Y-S, et al. (1995). Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond. Drug Metab Disp, 23, 1297-1300.
15. Bobo RH, Laske DW et al (1994). Convection enhanced delivery of macromolccules in the brain. Proc Natl Acad Sci USA 91: 2076-2080.
16. Boschi G, Launay N et al (1995). Brain microdialysis in the mouse. J Pharmacol Toxicol Meth 33: 29-33.
17. Bradbury M (1979). The Concept of a Blood-Brain Barrier. J. Wiley: New York.
18. Bradbury MWB (1992). Physiology and Pharmacology of the Blood-Brain Barrier. Springer Verlag: Berlin.
19. Bradley WG (1992). Magnetic resonance imaging in the evaluation of cerebrospinal fluid flow abnormalities. Magn Reson Quart 8: 169-196.
20. Brewster ME, Pop E et al (1993). The effect of dihydronicontinate N-substitution on the brain targeting efficacy of a zidovudine chemical delivery system. Pharm Res 10: 1356-1362.
21. Budinger TF, Huesman RH (1985). Ten precepts for quantitative data acquisition and analysis. Circulation 72 (Suppl 4): 53-62.
22. Burger DM Meenhorst PL et al (1995). Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Pharm World Sci 17: 25-30.
23. Chem T-L, Miller PS et al (1990). Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single iv injection into mice. Drug Metab Disp 18: 815-818.
24. Chlasson BJ, Hong M et al (1996). Antisense therapeutics in the central nervous system: the induction of c-fos. In Antisense Therapeutics. Agrawal S (ed): Humana Press: Totowa, N.J., pp. 225-246.
25. Chu CK, Bhadti VS et al (1990). Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of hihydropyridine derivatives of 3′-azido-2′,2′-dideoxyuridine and 3′-azido-3′-dideoxythymidine. J Med Chem 33: 2188-2192.
26. Cohn SE, Nawaz T et al (1996). Antiviral Agents. In A Practical Approach to Infectious Diseases. Reese RE, Betts RF (ed): Little, Brown and Co.: Boston, pp. 967-1036.
27. Collins JM, Dedrick RL (1983). Distributed model for drug delivery to CSF and brain tissue. Am J Physiol 14: R303-R310.
28. Cornford EM, Oldendorf WH (1975). Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta 394: 211-219.
29. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267: 1181-1190.
30. Cremer JE, Seville MP (1983). Regional brain blood flow, blood volume and hematocrit values in the adult rat. J Cereb Blood Flow Metab 3: 254-256.
31. Crone C (1963). The permeability of capillaries in various organs as determined by the use of the 'indicator diffusion' method. Acta Physiol Scand 59: 292-305.
32. Crooke ST, Graham MJ et al (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277: 923-937.
33. Cserr HF, Cooper DN et al (1977). Flow of cerebral interstitial fluid as indicated by the removal of extracellular markers from rat caudate nucleus. Exp Eye Res 25 (Suppl): 461-473.
34. Cserr HF, Cooper DN et al (1981). Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol 240: F319-F328.
35. Davis SS (1997). Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. TIBTECH 15: 217-224.
36. Davson H, Segal MB (1996). Physiology of the CSF and Blood-Brain Barriers. CRC Press: Boca Raton.
37. de Lange EC, Hesselink MB et al (1995). The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics. Pharm Res 12, 129-133.
38. Denissen JF, Grabowski BA et al (1997). Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Disp 25: 489-501.
39. Dudley MN (1995). Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 171: S99-112.
40. Dykstra KH, Arya A et al (1993). Microdialysis study of zidovudine (AZT) transport in rat brain. J Pharm Exp Ther 267: 1227-1236.
41. Fenstermacher JD (1989). Pharmacology of the blood-brain barrier. In Implications of the Blood-Brain Barrier and Its Manipulation. Neuwelt EA (ed): Plenum Medical Book Co: New York, pp. 137-155.
42. Fenstermacher JD, Blasberg RG et al (1981). Methods for quantifying the transport of drugs across brain barrier systems. Pharmacology and Therapeutics 14: 217-248.
43. Fenstermacher JD, Rall DP et al (1970). Ventriculocisternal perfusion as a technique for analysis of brain capillary permeability and extra-cellular transport. In: Capillary Permeability. Crone C, Lassen NA (ed): Academic Press; New York, pp. 484-490.
44. Fink DJ, DeLuca NA et al (1996). Gene transfer to neurons using herpes simplex virus-based vectors. Ann Rev Neurosci 19: 265-287.
45. Fishman RA (1980). Cerebrospinal Fluid in Diseases of the Nervous System. W.B. Saunders Co: Philadelphia.
46. Flexner C, Hendrix C (1997). Pharmacology of antiretroviral agents. In AIDS: Biology, Diagnosis, Treatment and Prevention. DeVita VT, Hellman S, Roxenberg SA (ed): Lippincott-Raven: Philadelphia, pp. 479-493.
47. Galinsky RE, Hoesterey BL et al (1990). Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci 47: 781-788.
48. Gallo JM (1991). Pharmacokinetic models for anticancer and antiviral drugs following administrations as novel drug delivery systems. In Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. D'Argenio DZ (ed): Plenum Press: New York, pp. 21-36.
49. Gallo JM (1994). Delivery of anti-HIV nucleosides to the central nervous system. Advanced Drug Deliv Rev 14: 299-309.
50. Ghersi-Egea JF, Finnegan W, et al. (1996). Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience, 75, 1271-1288.
51. Greenwald RB (1997). Drug delivery systems: anticancer prodrugs and their polymeric conjugates. Exp Opin Ther Patents 7: 601-609.
52. Greitz D (1993). Cerebrospinal fluid circulation and associated intracranial dynamics. Acta Radiol 34 (Suppl): 1-23.
53. Iversen PL, Copple BL et al (1995). Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Letters 82/83: 425-430.
54. 32P]-labeled phosphodiester oligonucleotide coupled to a neutral avidin/monoclonal antibody conjugate. Drug Metab Disp 23: 55-59.
55. Kessler JA, Fenstermacher JD et al (1976). Spinal subarachnoid perfusion of rhesus monkeys. Am J Physiol 230: 614-618.
56. Kimberlin DW, Spector SA et al (1995). Assays for antiviral drug resistance. Antiviral Res 26: 403-413.
57. Kuhl DE, Alavi A et al (1980). Local cerebral blood volume in head-injured patients. J Neurosurg 52: 309-320.
58. Levin VA, Gilboe DD (1970). Blood volume, hematocrit and pressure relationship in the isolated perfused dog brain. Stroke 1: 270-277.
59. Levy RM, Ward S, et al. (1997). Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain. J Neurovirol, 3, S74-S75.
60. Lin JH, Chiba M et al (1996). Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Disp 1111-1120.
61. Lu D, Raizada MK (1995). Delivery of angiotensin II type 1 receptor antisense inhibits angiotensin action in neurons from hypertensive rat brain. Proc Natl Acad Sci USA 92: 2914-2918.
62. Masereeuw R, Jaehde U et al (1994). In vitro and in vivo transport of zidovudine (AZT) across the blood brain barrier and the effect of transport inhibitors. Pharm Res 11: 324-330.
63. McCarthy MM, Nielsen DA et al (1995). Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brain. Regulatory Peptides 59: 163-170.
64. McCarthy MM, Schlenker EH et al (1993). Enduring consequences of neonatal treatment with antisense oligodeoxynucleotides to estrogen receptor messenger ribonucleic acid on sexual differentiation of rat brain. Endocrinology 133: 433-439.
65. Milhorat TH (1975). The third circulation revisited. J Neurosurg 42: 628-645.
66. Morgan ME, Singhal D et al (1996). Quantitative assessment of blood-brain barrier damage during microdialysis. J Pharmacol Exp Ther 277: 1167-1176.
67. Morrison PF, Laske DW et al (1994). High flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266: R292-305.
68. Nakagawa H, Groothuis DR et al (1988). Dexamethasone effects on vascular volume and tissue hematocrit in experimental RG-2 gliomas and adjacent brain. J Neurooncol 6: 157-168.
69. Nau R, Zysk G et al (1993). Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. Europ J Clin Pharmacol 45, 469-475.
70. Ohno K, Pettigrew KD et al (1978). Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235: H299-H307.
71. Oldendorf WH (1970). Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 24: 372-376.
72. Parsons LH, Justice JB (1994). Quantitative approaches to in vivo brain microdialysis. Critical Rev Neurobiol 8: 189-220.
73. Patlak CS, Fenstermacher JD (1975). Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion. Am J Physiol 229: 877-884.
74. Patlak CS, Blasberg RG et al (1983). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1-7.
75. Rapoport SI (1976). Blood-Brain Barrier in Physiology and Medicine. Raven Press; New York.
76. 14C]urea pharmacokinetics. Am J Physiol 242: R339-R348.
77. Rapoport SI (1983). Passage of proteins from blood to cerebrospinal fluid. Model for transfer by pores and vesicles. In Neurobiology of Cerebrospinal Fluid. Wood JH (ed): Plenum Press: New York, pp. 233-246.
78. Renkin EM (1959). Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscle. Am J Physiol 197: 1205-1210.
79. Robinson PJ, Rapoport SI (1990). Model for drug uptake by brain tumors: effect of osmotic treatment and of diffusion in brain. J Cereb Blood Flow Metab 10: 153-161.
80. Rosenberg GA, Kyner WT et al (1980). Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am J Physiol 238: F42-F49.
81. Saijo Y, Perlaky L et al (1994). Pharmacokinetics, tissue distribution, and stability of antisense oligonucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 6: 243-249.
82. Sakai F, Nakazawa K et al (1985). Regional cerebral blood volume and hematocrit measured in normal human volunteers by single-photon emission computed tomography. J Cereb Blood Flow Metab 5: 207-213.
83. Sakai RR, He PF et al (1994). Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J Neurochem 62: 2053-2056.
84. Sakai RR, Ma LY et al (1995). Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat. (Regulatory Peptides 59: 183-192.
85. Silverstein H (1996). Poster Presentation. International Conference on AIDS. Vancouver, BC.
86. Spector R, Spector AZ et al (1977). Model for transport in the CNS. Am J Physiol 232: R73-R79.
87. Spector R (1980). Thymidine transport in the CNS. J Neurochem 35: 1092-1098.
88. Spector R (1982). Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. J Pharmacol Exp Ther 222: 1-6.
89. Spector R, Eells J (1984). Deoxynucleoside and vitamin transport into the central nervous system. Fed Proc 43: 196-200.
90. Spector R (1985a). Thymidine transport and metabolism in choroid plexus: effect of diazepam and thiopental. J Pharmacol Exp Ther 235: 16-19.
91. Spector R (1985b). Uridine transport and metabolism in the central nervous system. J Neurochem 45: 1411-1418.
92. Stahle L (1993). Microdialysis in pharmacokinetics. Europ J Drug Metab Pharmacokin 18: 89-96.
93. Szklarczyk A, Kaczmarek L (1995). Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain. J Neurosci Methods 60: 181-187.
94. Takasawa K, Terasaki T et al (1997). In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 369-375.
95. Terasaki T, Pardridge WM (1988). Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J Infect Dis 158: 630-632.
96. Walker WL, Cook J (1996). Drug delivery to brain tumors. Bull Mathemat Biol 58: 1047-1074.
97. Wang L, Morin KW et al (1996). In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy (or ethoxy)-5,6-dihydro-3′-azido-3′-deoxythymidine diastereomers as potential prodrugs of 3′-azido-3′-deoxythymidine. J Med Chem 826-833.
98. Wang Y, Sawchuk RJ (1995). Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 84: 871 -876.
99. West ML, Fairlie DP (1995). Targeting HIV-1 protease: a test of drug-design methodologies. Trend in Pharm Sci 16: 67-75.
100. Westergren I, Nystrom B et al (1995). Intracerebral dialysis and the blood brain barrier. J Neurochem 64, 229-234.
101. Whitesell L, Geselowitz D et al (1993). Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implications for therapeutic application with the central nervous system. Proc Natl Acad Sci USA 90: 4665-4669.
102. Wong SL, Van Belle K et al (1993). Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharm Exp Ther 264: 899-909.
103. Wood JH (1980). Neurobiology of Cerebrospinal Fluid. Plenum Press: New York.
104. 3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther 276: 206-211.
105. Yaida Y, Nowak TS (1995). Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Regulatory Peptides 59: 193-199.
106. Yasdanian M (1997). Poster Presentation. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC.